Senores Pharmaceuticals: Why Did This Pharma Stock Rally 150%? Is There More Upside Ahead?

Synopsis:- A mid-cap pharma company that barely registers on most retail investors’ radar has quietly delivered one of the sharper rallies in the sector this year, backed by genuine 110 percent profit growth and an aggressive US expansion, though a rich valuation and a working capital cycle that’s nearly doubled deserve just as much attention as the headline numbers.

A mid-cap stock most retail investors have probably never heard of is quietly running one of the sharper rallies in the market this year, up nearly 150 percent from its 52-week low. The move isn’t just sentiment either, the underlying business has genuinely delivered, beating its own growth guidance for eight straight quarters and expanding aggressively into new markets.

Senores Pharmaceuticals Limited was trading at Rs. 1,420, with a market capitalization of Rs. 6,539.61 crore. The stock has climbed roughly 150 percent off its 52-week low of Rs. 558.55, and is trading at a P/E of 56.67. Recently, the stock has even touched its 52- week high of Rs.1,487.90.

The Numbers That Justify the Rally

Strip away the noise and the underlying business did genuinely well. FY26 revenue came in around Rs.664 crore, up 62 percent year-on-year, while profit after tax more than doubled to Rs. 122 crore, comfortably beating the company’s own guidance of 50 percent revenue growth and 100 percent PAT growth for the year.Q4 alone saw consolidated income jump 58 percent year-on-year to Rs. 190 crore, with EBITDA nearly tripling and margins expanding almost 1,150 basis points to 32.7 percent. 

This isn’t a company squeaking past expectations. It’s one that’s been beating its own guidance for eight straight quarters since its IPO, according to management, which is the kind of consistency that tends to earn a stock a valuation premium rather than a discount.

Where the Growth Is Actually Coming From

The regulated markets business, largely the US, did the heavy lifting, growing 74.6 percent for the year to Rs. 427 crore. Behind that number is a genuinely aggressive ANDA strategy: the company’s approved portfolio more than doubled from 26 products in March 2025 to 51 in March 2026, with 21 already commercially launched and another 57 expected to roll out over the next six to eight quarters. 

Management is also stitching together a broader US presence through acquisitions, picking up a majority stake in Apnar Pharma’s USFDA-approved manufacturing facility during Q4, buying Zoraya Pharmaceuticals to strengthen US distribution, and entering a joint venture called Amerisyn aimed at cracking US federal and Veterans Affairs procurement contracts, a market that’s historically been hard for smaller Indian generics players to access directly. 

Management is guiding for the US business, combining Indian and American manufacturing, to reach Rs. 2,500 to 3,000 crore in revenue within three to four years, an ambitious number that would represent roughly four to five times the current run rate.

Financial Distress

Working capital days jumped from 114 in FY25 to 187 in FY26, and management’s answer was that the Apnar acquisition inflated the number since sales from that facility hadn’t started flowing through yet, with the underlying core business running closer to 104 days.

That’s a reasonable explanation, but it’s also exactly the kind of answer that needs verifying over the next couple of quarters rather than taking it at face value, since an acquisition-driven working capital spike that doesn’t normalise on schedule is a classic way for a fast-growing company to quietly build cash flow stress. 

Another useful exchange covered “other financial assets,” which jumped from Rs. 116 crore to Rs. 172 crore. Management explained this reflects profit-share income recognised under accounting rules before the cash is actually collected, typically a one-to-six-month lag, which is a legitimate accounting treatment in this kind of B2B licensing model but is also worth tracking, since a growing gap between recognised profit and collected cash is one of the more subtle red flags in fast-scaling pharma businesses.

FY27 Guidance

Management guided FY27 revenue growth of 30 to 40 percent and PAT growth of 50 to 60 percent, numbers that sound like a deceleration from FY26’s 60 and 110 percent respectively. 

When pressed by an analyst on why the guidance looked conservative given an accelerating product pipeline, management’s answer was blunt: global shipping disruptions, US inflationary pressure, and general macro uncertainty made them want to under-promise for a quarter or two before revising upward. 

Senores Pharmaceuticals is a Gujarat-based, research-driven pharmaceutical company developing and manufacturing complex generics, critical care injectables, and APIs for regulated markets including the US, UK, and Canada, alongside a growing emerging markets and Indian branded generics footprint. The company listed in December 2024 and has continued acquiring manufacturing assets and distribution capability in the US to support its ANDA pipeline.

For retail investors, the growth engine here looks real rather than manufactured, but the valuation has already priced in a good chunk of that growth story, and the working capital trend is the one number worth watching before assuming this rally has room to run uninterrupted.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Senores Pharmaceuticals: Why Did This Pharma Stock Rally 150%? Is There More Upside Ahead? appeared first on Trade Brains.